Southern California's
Tech
Startup Directory
Showcasing Southern California's innovation, one startup at a time. Every funded and bootstrapped company, from seed round to first dollar of revenue, tracked as it happens.
Includes SEC Form D filings from the last 3 years, plus all-time totals for companies sourced from YC and news coverage.
Artificial Intelligence
The region's largest single cluster by company count — AI and machine learning threaded through nearly every other industry here, from defense to biotech to entertainment.
Aerospace & Defense
Home to SpaceX, Northrop Grumman, and a new wave of hypersonics and space-infrastructure startups.
Entertainment & Gaming Tech
Hollywood's production infrastructure, live events, and a growing games and creator-tools scene.
Semiconductor Hardware
Qualcomm and Broadcom anchor a chip-design cluster spanning the region.
Medical Technology
A deep biotech research base and a growing bench of medical device and diagnostics startups.
B2B
Business software and services sold to other companies. The largest single category of startup across Southern California, spanning sales tools, vertical operating systems, and everything in between.
Industrials
Manufacturing, hardware, and physical-world operations. Overlaps heavily with the region's decades-old aerospace and defense manufacturing base, now extending into robotics and automated production.
Consumer
Products and apps built directly for individual consumers, drawing on Southern California's media and entertainment base.
Healthcare
Health tech, medical devices, and healthcare services, backed by a decades-old biotech research base and a deep bench of clinical and diagnostics startups.
Fintech
Financial technology: payments, banking, investing, and financial infrastructure.
Education
Education technology and learning platforms built across Southern California.
Real Estate & Construction
Property technology, construction tech, and real estate services.
Merck agreed to acquire the San Diego biotech for approximately $9.2 billion in November 2025.
Co-founded by Drew Weissman, the 2023 Nobel Prize winner in Physiology or Medicine for mRNA vaccine research, alongside CAR-T pioneer Carl June; the company was later acquired by AbbVie.
Series B$212.1MScience Seralutinib Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Series B$200.0MCo-founded by CEO Todd Harris and COO Daniel Bensen, and was incubated by venture firm Alta Partners before going public.
Series B$172.8MWe are on a mission to exponentially improve the number of quality years for patients.
Series B$155.8MEquip was co-founded by CEO Kristina Saffran, who drew on her own recovery from anorexia; she previously co-founded the nonprofit Project Heal. Actress Kerry Washington has also personally invested in the company.
Series B$152.2MWe are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.
Series B$150.0MOur mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.